Global Prostate Cancer Drugs Market 2016-2020


#892967

91pages

Technavio

$ 2500

In Stock

About Prostate Cancer Drugs
Prostate cancer is the cancer of prostate gland. According to CDC, it is one of the leading cause of cancer death in men across the races in the US. According to the Urology Care Foundation, globally, one in seven men will be diagnosed with the disease. About one in 35 men die due to prostate cancer. Growth in the prostate can be benign or malignant. Prostate cancer cells spread by breaking away from a prostate tumor. They may travel through blood vessels or lymph vessels and reach other parts of the body. The cells that spread might bind to other tissues, form new tumors, and sometimes damage those tissues as well. When prostate cancer cells spread from their original place to another, the new tumor formed also has the same kind of abnormal cells.

Technavios analysts forecast the global prostate cancer drugs market to grow at a CAGR of 9.21% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global prostate cancer drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of drugs that expected to be launched into the market along with the decline in revenues from the genericization of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography:
Americas
APAC
EMEA

Technavio's report, Global Prostate Cancer Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
AbbVie
Astellas Pharma
AstraZeneca
Johnson & Johnson
Sanofi

Other prominent vendors
Active Biotech
ADC Therapeutics
Advantagene
Advaxis Pharmaceuticals
ANI Pharmaceuticals
ArQule
Athenex Pharmaceuticals
Bavarian Nordic
Bayer HealthCare
BHR Pharma
BMS
Boehringer Ingelheim
Camurus
Cleveland BioLabs
CureVac
Dendreon
Dextech Medical
Eisai
Endo Pharmaceuticals
Ferring Pharmaceutical
Foresee Pharmaceuticals
GlaxoSmithKline
GTx
Innocrin Pharmaceutical
Inspyr Therapeutics
Io Therapeutics
Lidds AB
Merck Group
Myovant Sciences
Northwest Biotherapeutics
Novartis
Nymox Pharmaceuticals
OncoGenex
Oncolytics Biotech
Orion
Pharmamar
Progenics Pharmaceuticals
Sotio
Spectrum Pharmaceuticals
Synta
Takeda Pharmaceuticals
Teva Pharmaceutical
Tokai Pharmaceuticals

Market driver
Physicians preference toward adopting hormonal therapies
For a full, detailed list, view our report

Market challenge
Presence of alternative treatment approaches
For a full, detailed list, view our report

Market trend
Emergence of targeted therapies and immunotherapies
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.